Cincinnati · Montgomery · Edgewood, KY By appointment · Most insurance accepted
Contact
Request a Consultation

RegenLife Centers · Physician-led care

Osteoporosis and Bone Health

Can Regenerative Medicine Strengthen Bone?

Published on November 7th, 2026

Caitlyn Benton
Written by
Caitlyn Benton
Dr. Zeeshan Tayeb
Reviewed and Approved by
Dr. Zeeshan Tayeb

The 62-year-old woman who fractures a vertebra reaching for a box on a shelf, who assumed her back pain was muscular and her rounded posture was simply age, rarely knows that the silent, progressive bone loss responsible for that fracture has been measurable on a DEXA scan for a decade, that half of all women over 50 will fracture a bone due to osteoporosis in their lifetime, and that the treatment pathway she is most likely to receive, a bisphosphonate prescription with a follow-up in a year, addresses the symptom of bone loss without evaluating the hormonal, metabolic, and biological environment that drove it. The woman who is told her T-score is -2.6 and handed a calcium supplement and a pill that 50% of patients stop taking within twelve months because of side effects they find intolerable: this patient is being managed by the structural minimum of a condition whose biological complexity modern regenerative medicine is increasingly equipped to address at the level it actually operates.

Osteoporosis and bone health treatment at RegenLife Centers for Integrative Pain & Weight Management begins from a premise that the standard pharmacological management pathway does not consistently reflect: that osteoporosis affects approximately 10.2 million Americans over age 50, with an additional 43 million in the osteopenia range that precedes it, and that the fracture cascade it produces costs the U.S. healthcare system billions of dollars annually and shortens lives, and that the regenerative and lifestyle medicine approaches now supported by clinical evidence offer a biologically coherent pathway for slowing bone loss, improving fracture resilience, and optimizing the systemic hormonal and metabolic environment that bone remodeling requires, approaches that the patient handed a bisphosphonate and sent home may never have been offered.

A cheerful senior woman holding a yoga mat, embracing an active and healthy lifestyle as part of bone health managementA cheerful senior woman holding a yoga mat, embracing an active and healthy lifestyle as part of bone health management

Key Takeaways

  • Osteoporosis affects 10.2 million Americans over 50 and generates 9 million fractures annually worldwide: yet standard bisphosphonate treatment has a 50% discontinuation rate within one year, and no pharmacological approach addresses the hormonal, metabolic, and biological contributors that determine how rapidly bone loss progresses
  • Mesenchymal stem cell therapy directly rebalances the osteoblast-to-osteoclast ratio that bone density depends on: targeting the cellular mechanism of osteoporosis rather than suppressing bone remodeling pharmacologically, with early clinical evidence supporting its role in bone regeneration
  • Resistance training produces an average 1.82% increase in bone mineral density at loading sites and represents the highest-evidence non-pharmacological intervention for bone density preservation; combined with optimized hormonal and nutritional status, it creates the systemic environment in which regenerative approaches achieve meaningful effect
  • Hormonal deficiency: estrogen, testosterone, and growth hormone, is among the most clinically significant and undertreated contributors to bone loss, and patients whose bone density decline is driven by unaddressed hormonal insufficiency are being treated for the result while the cause continues operating

Understanding Osteoporosis: What Bone Loss Actually Means Biologically

The Balance Between Osteoblasts and Osteoclasts

Bone is not a static structural material. It is a living tissue in continuous remodeling: osteoclasts, bone-resorbing cells, break down aging bone matrix, releasing the calcium and collagen into the bloodstream, while osteoblasts, bone-forming cells, deposit new bone matrix that then mineralizes to replace what was removed. Under normal conditions, this remodeling cycle maintains bone density within a narrow range; osteoporosis develops when the balance shifts toward resorption, when osteoclast activity outpaces osteoblast repair, and the structural architecture of the bone progressively deteriorates. The trabecular lattice that gives cancellous bone its weight-bearing strength becomes progressively perforated, cortical bone thins, and the mechanical competence of the skeleton declines well before any fracture signals the process to the patient or their clinician.

The key biological insight, the one the standard pharmacological approach acts on directly but without addressing its root, is that osteoporosis is not simply a calcium deficiency or even a bone density deficiency. It is a cellular dysregulation: a loss of the homeostatic balance between the cells whose job is to build bone and the cells whose job is to remove it. Bisphosphonates slow bone loss by suppressing osteoclast activity; they do not stimulate osteoblast bone formation. The pharmacological result is preserved quantity of existing bone, but not improved quality, not restored cellular balance, and not the biological repair of the trabecular microarchitecture that fracture resistance ultimately depends on. Regenerative approaches, by contrast, act on the cellular environment directly.

How Osteoporosis Becomes a Fracture Problem

Osteoporosis produces approximately 9 million fractures annually worldwide, and in the United States the consequences are concentrated in the hip, vertebral body, and distal radius, sites where trabecular bone predominates and where progressive architectural deterioration most directly translates into structural failure under loads that healthy bone tolerates without consequence. Hip fractures are the most clinically devastating: 20–30% of patients who fracture a hip die within one year, and the majority of survivors experience permanent functional limitation. Vertebral compression fractures produce the chronic axial pain and progressive thoracic kyphosis, the rounded upper back posture that patients attribute to "getting older", that represents years of accumulated compression under loads the demineralized vertebral body could no longer bear.

The fracture cascade, the well-documented phenomenon by which one fragility fracture multiplies the risk of subsequent fractures, is the outcome the standard management pathway most urgently needs to interrupt. Within four years of a first fracture, cumulative second-fracture rates reach nearly 21%, and each subsequent fracture compounds the functional decline and mortality risk. This is the timeline within which the choice of management approach, pharmacological suppression alone versus a comprehensive biological and lifestyle intervention, carries its greatest clinical weight.

Who Is Most at Risk and Why

Osteoporosis affects 18.8% of women over 50 and 4.2% of men in the same age group, with the sharp gender disparity primarily reflecting the abrupt estrogen decline of menopause: estrogen suppresses osteoclast activity, supports calcium absorption, and maintains the anabolic signaling environment that osteoblast function requires; its withdrawal at menopause removes a major protective signal from the bone remodeling system, and the resulting resorption surge can cost a woman 20% of her bone mass in the first five to seven years following her last menstrual cycle. Men experience a more gradual androgen decline without the abrupt hormonal shift, which explains both the lower prevalence and the later peak incidence of osteoporosis in the male population, but men who develop osteoporosis suffer equivalent or greater fracture morbidity, and their condition is diagnosed and treated at lower rates than in women.

Beyond hormonal status, the risk profile for accelerated bone loss includes: glucocorticoid medication use (which directly suppresses osteoblast activity and accelerates bone resorption), inflammatory conditions including rheumatoid arthritis and Crohn's disease, diabetes mellitus, malabsorptive gastrointestinal conditions that impair calcium and vitamin D absorption, smoking, excessive alcohol intake, and low body weight, the latter reflecting the relative absence of the mechanical loading stimulus that weight-bearing exercise and adipose tissue mass both contribute to maintaining bone density.


Diagnosing Osteoporosis and the Limits of Standard Management

High-resolution radiological x-ray images of the human spine used for medical examination and bone density diagnosisHigh-resolution radiological x-ray images of the human spine used for medical examination and bone density diagnosis

DEXA Scanning and T-Scores: What the Measurement Tells You

The DEXA scan, dual-energy X-ray absorptiometry, is the gold standard for measuring bone mineral density and remains the primary diagnostic tool for osteoporosis and osteopenia. DEXA measures BMD at the lumbar spine, total hip, and femoral neck, comparing the patient's result against a reference database of peak bone mass in young healthy adults to generate the T-score that defines diagnostic categories: T-score of -1.0 or above is normal; -1.0 to -2.5 is osteopenia; -2.5 or below is osteoporosis. The FRAX fracture risk calculator extends the diagnostic picture by integrating ten clinical variables, including age, prior fracture history, parental hip fracture, steroid use, and secondary osteoporosis contributors, to generate a 10-year fracture probability that guides treatment decisions, particularly in the osteopenic range where T-score alone may not trigger treatment while fracture risk may warrant it.

What DEXA does not tell the clinician is why the bone density is low, whether the driver is estrogen deficiency, testosterone insufficiency, growth hormone decline, glucocorticoid exposure, vitamin D and K2 insufficiency, sedentary lifestyle, or some combination of these contributors operating simultaneously. A T-score of -2.7 is an outcome, not a cause; treating the outcome without characterizing the cause is the structural gap in the standard pharmacological management pathway that a comprehensive evaluation addresses.

The Bisphosphonate Problem

Bisphosphonates, alendronate, risedronate, ibandronate, and zoledronic acid, are the most widely prescribed first-line pharmacological treatment for osteoporosis, and they reduce fracture risk by suppressing osteoclast-mediated bone resorption through a well-characterized mechanism. The clinical problem is not their mechanism; it is the gap between their effectiveness when taken consistently and the rate at which patients actually take them. Bisphosphonate non-compliance rates reach 50% within the first year of treatment, and only 43% of patients continue treatment at 12–24 months, driven primarily by gastrointestinal side effects including heartburn, esophageal irritation, nausea, and bone and joint pain. The oral dosing requirements, a full glass of water, upright positioning for 30 minutes, no food for an hour, create a daily or weekly ritual that patients experience as burdensome and that those with pre-existing esophageal or gastrointestinal conditions may not be able to manage safely.

Rare but serious adverse effects, osteonecrosis of the jaw occurring at approximately 0.10% prevalence in osteoporosis patients, and atypical femoral fractures with long-term use, generate warranted caution in patients who receive them without adequate counseling. And bisphosphonates address none of the hormonal, metabolic, or lifestyle contributors that drove the bone loss in the first place. The patient who takes alendronate weekly but has untreated testosterone deficiency, vitamin D insufficiency, insulin resistance, and a sedentary lifestyle is receiving a partial intervention for a multidimensional problem.


Regenerative Medicine for Bone Health: The Biological Repair Argument

A medical professional drawing blood from a patient in a clinical setting, a key step in PRP regenerative therapy preparationA medical professional drawing blood from a patient in a clinical setting, a key step in PRP regenerative therapy preparation

PRP Therapy: Growth Factors and Bone Regeneration

PRP therapy concentrates the patient's own platelets to 3–8 times their baseline blood levels, delivering platelet-derived growth factor (PDGF), transforming growth factor-beta (TGF-β), vascular endothelial growth factor (VEGF), and insulin-like growth factor-1 (IGF-1) directly to target tissues under image guidance. In the context of bone health, these growth factors are the biological signals that support osteoblast proliferation, stimulate angiogenesis at remodeling sites, and modulate the pro-inflammatory cytokine environment that promotes osteoclast-driven bone breakdown. Meta-analysis data show that pure platelet-rich plasma significantly promotes new bone formation, and studies combining PRP with hydroxyapatite grafting demonstrate a 15% increase in bone density and 10% increase in bone height at six-month follow-up, outcomes that reflect the synergy between PRP's growth factor payload and an osteoconductive scaffold.

The clinical application of PRP in osteoporosis management is most mature in the context of fracture healing acceleration and periarticular bone quality, particularly in spinal and hip presentations where compromised bone biology prolongs recovery and increases the risk of hardware failure following surgical fixation. For patients with established osteoporosis who sustain vertebral compression fractures, PRP's role in supporting bone healing biology represents a meaningful adjunct to the structural interventions used to stabilize the fracture, not a standalone alternative, but a biologically coherent addition to the treatment sequence that addresses what pharmacological approaches do not. As the evidence base for PRP in systemic bone density improvement develops, current data support its targeted application at fracture sites and in combination with other regenerative modalities rather than as a replacement for the hormonal and nutritional optimization that systemic bone loss requires.

Mesenchymal Stem Cell Therapy: Rebalancing the Cellular Equation

Mesenchymal stem cell therapy represents the most mechanistically direct regenerative approach to osteoporosis, addressing not the downstream symptoms of the osteoblast-osteoclast imbalance but the cellular machinery generating it. MSCs are multipotent progenitor cells capable of differentiating into osteoblasts, chondrocytes, and adipocytes, and they carry a potent paracrine activity, releasing cytokines, growth factors, and signaling molecules that modulate the local cellular environment, that extends their therapeutic effect beyond direct differentiation into the tissues they are repairing.

In osteoporosis specifically, MSC therapy works by inducing differentiation of bone progenitor cells into osteoblasts, promoting angiogenesis at bone remodeling sites, and modulating the inflammatory environment that drives excess osteoclast activity, directly reestablishing the cellular balance that osteoporosis disrupts. Both bone marrow-derived and umbilical cord blood-derived MSCs have demonstrated promise in preclinical and early clinical evidence for bone regeneration, with umbilical cord-derived MSCs showing particular potential as an allogeneic source for patients whose autologous bone marrow MSC quality has been compromised by age-related senescence. The age-related decline in MSC osteogenic differentiation capacity, driven by increased oxidative stress, reduced growth factor responsiveness, and chronic low-grade inflammation, is a clinically relevant consideration: MSCs harvested from older patients with osteoporosis have reduced regenerative potency compared to those from younger donors, which informs both patient selection and the case for optimizing the systemic inflammatory environment before or alongside MSC therapy.

The current evidence base for MSC therapy in osteoporosis is earlier in development than for peripheral joint applications, and patients should understand that this is an emerging application with growing but not yet definitive clinical trial data. What the existing mechanistic and preclinical literature establishes clearly is that MSC therapy addresses a target, the cellular balance between bone formation and resorption, that pharmacological management does not, creating a biological rationale for its role in comprehensive osteoporosis management that the clinical evidence base is progressively supporting.

Prolotherapy and Vertebral Stability

Prolotherapy applied to the spinal ligamentous attachments adjacent to osteoporotic vertebrae addresses the segmental instability that progressive vertebral height loss and posterior element degeneration produce, not by directly stimulating bone formation, but by restoring the passive connective tissue support that protects compromised vertebral bodies from the repetitive microloading that accelerates their structural failure. In patients with osteoporotic compression fractures, prolotherapy directed at the vertebral ligamentous complex helps stabilize the fracture site by promoting fibroblastic repair at fibro-osseous junctions, reducing the pain-generating micromotion that both delays healing and limits rehabilitation engagement. The biological rationale is the same as in peripheral joint application: ligamentous laxity creates abnormal loading patterns; restoring connective tissue integrity through targeted dextrose injection reduces the mechanical insult to the adjacent bony structures operating within a compromised biological environment.


Hormonal Optimization and Bone Density: The Most Undertreated Connection

Estrogen, Testosterone, and Bone Remodeling

The relationship between hormonal status and bone density is not background context for osteoporosis management. It is the primary biological mechanism driving bone loss in the majority of patients over 50, and its systematic undertreatment accounts for a large proportion of the inadequate treatment response that pharmacological management alone produces. Estrogen suppresses osteoclast activity, supports calcium absorption from the gut, and maintains the anabolic signaling environment that osteoblast function requires, its abrupt decline at menopause removes all three of these protective signals simultaneously, explaining why the early postmenopausal years represent the period of most rapid bone loss and why women who enter menopause without hormonal support face a bone density trajectory that calcium and vitamin D supplementation alone cannot interrupt.

Testosterone, in both men and women, directly promotes bone formation through androgen receptor signaling on osteoblasts, and research consistently identifies testosterone deficiency as an independent risk factor for osteoporosis, with low androgen levels correlating with lower BMD across both sexes. In men, the gradual androgen decline of aging, hypogonadism, produces the male analog of postmenopausal bone loss, and men with documented hypogonadism have fracture rates substantially higher than age-matched controls. The hormone therapy assessment at RegenLife evaluates estrogen, testosterone, DHEA, growth hormone, and cortisol profiles as integrated determinants of bone density trajectory, not as a secondary consideration after pharmacological treatment has been initiated, but as the foundational biological context that determines what kind of bone loss is occurring and which interventions are most likely to interrupt it.

Growth Hormone and the Anabolic Bone Environment

Growth hormone, acting primarily through insulin-like growth factor-1, is essential for maintaining bone density in adults, directly stimulating osteoblast proliferation and differentiation and promoting the synthesis of the collagen matrix that bone mineralization requires. Growth hormone deficiency in adults, whether following pituitary pathology, traumatic brain injury, or the age-related decline of somatotropic function, produces accelerated bone loss that standard osteoporosis pharmacotherapy does not address, because the drug's osteoclast-suppressing mechanism cannot compensate for the absence of the osteoblast-stimulating signal that growth hormone normally provides.

Patients with unexplained bone density decline who have not had growth hormone and IGF-1 levels evaluated are missing a potentially significant contributor to their trajectory, and those in whom deficiency is confirmed have access to the only anabolic pharmacological intervention that directly addresses bone loss from the formation side rather than the resorption side. The evaluation at RegenLife characterizes this hormonal dimension alongside the more commonly measured reproductive hormones, because the patient with concurrent estrogen deficiency, testosterone insufficiency, and growth hormone decline is experiencing three simultaneous anabolic signal reductions whose combined effect on bone density is multiplicatively greater than any single deficiency would produce.


Lifestyle Medicine for Bone Health: Exercise, Nutrition, and the Systemic Foundation

A senior woman using a lat pulldown machine in a gym, engaging in strength training to support bone density and musculoskeletal healthA senior woman using a lat pulldown machine in a gym, engaging in strength training to support bone density and musculoskeletal health

Weight-Bearing and Resistance Exercise: The Highest-Evidence Intervention

Resistance training produces an average 1.82% increase in bone mineral density at loaded skeletal sites in postmenopausal women, a modest but clinically meaningful effect when considered over the 20–30 year timeframe during which bone density management determines fracture outcomes. The mechanism is direct: mechanical loading of bone through muscle contraction and gravitational stress activates the mechanosensory pathways in osteoblasts and osteocytes that stimulate bone matrix synthesis, and the site-specificity of the response, bone density increases at loaded sites, means that a well-designed exercise program targeting the hip, spine, and wrist can protect the exact anatomic locations where osteoporotic fractures occur most frequently. A minimum of 15–20 minutes of resistance training three days per week produces measurable BMD improvement at the lumbar spine within six months of consistent practice, and meta-analytic evidence confirms that resistance training outperforms aerobic exercise for bone density outcomes, though weight-bearing aerobic activity such as walking and dancing contributes independently to the lower extremity and spinal loading that sedentary behavior forfeits entirely.

The balance and fall-prevention dimension of exercise for osteoporosis is as clinically important as the BMD effect: osteoporotic fractures require both fragile bone and a mechanical insult, most commonly a fall, to occur, and interventions that reduce fall risk by improving neuromuscular coordination, reaction time, and lower extremity strength produce fracture prevention outcomes that operate independently of any improvement in bone mineral density. The exercise therapy and physical therapy programs at RegenLife address both dimensions, the bone-loading stimulus that preserves density and the proprioceptive and balance training that reduces the fall probability against which that density must protect.

Nutrition for Bone Density: The Evidence Hierarchy

The nutritional foundation for bone health is more complex than the calcium-and-vitamin-D framework that most patients receive, and the interactions between micronutrients are clinically significant enough that optimizing one component without the others produces systematically incomplete outcomes. Calcium at 1,200 mg daily provides the raw material for bone mineralization but is demonstrably ineffective in the early postmenopausal years when estrogen deficiency, not calcium availability, is the dominant determinant of bone resorption rate. The clinical implication is that calcium supplementation should accompany, not substitute for, hormonal and biological optimization in this patient population.

Vitamin D3 and K2 represent the combination with the strongest randomized controlled trial evidence for fracture risk reduction and bone mineral density preservation across the adult population: D3 supports intestinal calcium absorption and osteoblast function; K2 (menaquinone) activates osteocalcin, the bone matrix protein that binds calcium to the hydroxyapatite crystal lattice, and activates matrix GLA protein, which prevents arterial calcification by ensuring the calcium that D3 mobilizes is deposited in bone rather than soft tissue. The synergy is mechanistic: D3 without K2 increases circulating calcium that may not reach its skeletal destination; K2 without adequate D3 and calcium has no substrate to direct. Magnesium completes the cascade. It activates the enzyme that converts vitamin D to its active form, and low extracellular magnesium independently promotes osteoclast activity while suppressing osteoblast proliferation. The lifestyle medicine evaluation at RegenLife includes the nutritional status assessment, vitamin D, K2, magnesium, and comprehensive metabolic markers, that determines which components of the nutritional foundation are deficient and allows precise repletion rather than generic supplementation.


When Surgery Is the Right Answer: Vertebroplasty and Kyphoplasty

Indications for Surgical Fracture Management

Vertebral compression fractures, the most common consequence of osteoporotic bone loss, affecting approximately 700,000 Americans annually, produce the axial pain and height loss that define the clinical course of advanced osteoporosis, and most heal sufficiently with conservative management including activity modification, pain control, and spinal orthosis. The subset that does not, fractures producing severe, refractory pain unresponsive to several weeks of conservative therapy, or those where progressive vertebral collapse threatens spinal stability or neural element compression, are appropriate candidates for the surgical augmentation procedures that vertebroplasty and kyphoplasty provide.

Vertebroplasty stabilizes the fractured vertebra by injecting polymethylmethacrylate bone cement directly into the fractured body under fluoroscopic guidance, producing immediate structural consolidation and pain relief through the thermal and mechanical effects of cement polymerization on the intraosseous nociceptors generating the fracture pain. Kyphoplasty adds a balloon inflation step prior to cement injection, which creates a cavity within the vertebral body and partially restores the height that compression has lost, reducing the kyphotic deformity that accumulated vertebral collapse produces and potentially reducing the adjacent-level loading that kyphosis concentrates on neighboring vertebrae. Both procedures demonstrate greater pain relief and functional outcome improvement than conservative management in clinical trials, with kyphoplasty showing superior quality of life improvement over conservative treatment alone.

What Surgery Does Not Address

Vertebroplasty and kyphoplasty are structural solutions for an individual fracture. They stabilize the vertebra that has already failed without addressing the bone biology that caused it to fail or protecting the adjacent levels from the same fate. The patient who undergoes kyphoplasty for an L2 compression fracture without initiating comprehensive osteoporosis management, hormonal optimization, nutritional repletion, resistance training, and appropriate pharmacological support where indicated, has a substantially elevated risk of fracturing L1 or L3 within the following two years, as the mechanical demand that the treated level previously bore redistributes upward and downward onto vertebrae whose structural integrity the same biological process has compromised. The 4-year cumulative second-fracture rate of nearly 21% in inadequately managed patients is not an inevitable consequence of osteoporosis. It is the predictable outcome of structural repair without biological management.


The Integrated Evaluation at RegenLife: Osteoporosis Cincinnati OH

Comprehensive osteoporosis management begins with an evaluation that goes beyond T-score and bisphosphonate selection to characterize the hormonal, metabolic, and nutritional contributors that determine how rapidly bone loss is progressing and how completely the patient's biological environment supports repair. The diagnostic services at RegenLife integrate DEXA-derived bone density data with complete hormonal panels, estradiol, testosterone, free testosterone, DHEA-S, growth hormone, and IGF-1, vitamin D status, inflammatory markers, and the metabolic screening that identifies insulin resistance and thyroid dysfunction as independent contributors to bone density decline. Patients who have received a pharmacological prescription without this systematic evaluation have been treated for their T-score, not for the biological system that produced it.

The systemic factors that independently impair bone density and regenerative treatment response are not incidental findings. They are the primary targets. Insulin resistance reduces osteoblast function and promotes the inflammatory environment that amplifies osteoclast activity. Elevated systemic inflammation, reflected in CRP and cytokine profiles, drives the bone remodeling balance toward resorption regardless of what pharmacological suppression is applied locally. Testosterone deficiency, estrogen decline, and growth hormone insufficiency each remove a critical anabolic signal from the osteoblast environment; their combined absence in a postmenopausal woman with untreated hypogonadism creates a bone-forming deficit that neither bisphosphonates nor calcium can compensate. The hormone therapy protocol at RegenLife addresses these deficiencies directly, because the patient with optimized hormonal and metabolic status is a fundamentally different biological environment for bone density preservation, and for regenerative intervention, than one whose anabolic capacity remains depleted.

The treatment sequence, hormonal optimization addressing the primary biological drivers, nutritional repletion of the micronutrient cofactors bone remodeling requires, resistance and weight-bearing exercise providing the mechanical stimulus osteoblasts respond to, PRP or MSC therapy for targeted bone biological support where indicated, and pharmacological fracture prevention where fracture risk warrants it, is selected and ordered based on diagnostic findings rather than applied uniformly. Related structural considerations in the spine that often accompany osteoporosis are addressed in our posts on degenerative disc disease non-surgical treatment options and spinal stenosis treatment in Cincinnati, OH. The goal is not a suppressed T-score or a managed fracture: it is a bone biology restored as completely as the underlying contributors allow, on a timeline that comprehensive biological management makes achievable.


Contact RegenLife Centers to schedule an evaluation or ask which service fits your needs.


Frequently Asked Questions

Find answers to common questions

Ready to Learn More?

To learn more and to find out if you might be a good candidate at RegenLife, schedule a consultation with our team today.

About the Author

Caitlyn Benton

Caitlyn Benton, Research Manager at RegenLife

As Research Manager, Caitlyn Benton oversees the strategic planning and execution of clinical research projects, ensuring all studies adhere to the highest regulatory and ethical standards. With expertise in protocol development and data monitoring, she coordinates multidisciplinary teams to ensure the integrity of our clinical research programs and the accuracy of the insights shared with our patients.

Reviewed and Approved by

Dr. Zeeshan Tayeb

Dr. Zeeshan Tayeb, Medical Director at RegenLife

Interventional Spine, Pain, and Sports Medicine Dr. Zeeshan Tayeb, MD is board-certified in Pain Medicine and Physical Medicine & Rehabilitation, with specialized fellowship training in interventional spine, pain, and sports medicine. He sees patients at Pain Specialists of Cincinnati/RegenLife in Cincinnati, Ohio. Dr. Tayeb's background in physical medicine and rehabilitation has provided the foundation for his comprehensive approach to treating the whole person. Dr. Tayeb has done extensive training and education in both functional and regenerative medicine and specializes in state-of-the-art treatments, including laser therapies, PRP and stem-cell injections, and nutritional and hormonal optimization.

Disclaimer:

As a service to our readers, RegenLife provides access to our library of archived content. Please note the date of last review or update on all articles.

No content on this site, regardless of date, should ever be used as a substitute for direct medical advice from your doctor or other qualified clinician.

Stay Updated With Our Latest News

Check back regularly for new articles and updates about pain management treatments, practice news, and health tips from our team of specialists.

Get In Touch

Same-week consults. Real follow-through.

Tell us what's going on. A coordinator will follow up during office hours to help book your visit.

Request a consultation

Choose the clinic that works for you.

Most new patients can be seen within the same week.

Cincinnati

3328 Westbourne Dr

Cincinnati, OH 45248

(513) 922-2204

Edgewood

162 Barnwood Dr

Edgewood, KY 41017

(859) 331-4159

Montgomery

9989 Montgomery Rd

Montgomery, OH 45242

(513) 922-2204

We accept most major insurance plans

Request